search Created with Sketch.
search Created with Sketch.

Advertisement

dermwire-tv-logo Created with Sketch.
dermwire-tv-logo Created with Sketch.

DermWireTV: Clinical Support Tech Data; Dupixent, Stelara Updates; Rihanna Launches Fenty Skin

August 13, 2020

A feasibility study in collaboration between LEO Innovation Lab, VisualDX, and the German Association of Dermatological Prevention supports technology to assist in diagnosis of skin conditions. Leo Pharma’s investigational JAK inhibitor delgocitinib cream is  Fast Tracked by the FDA for the potential treatment of adults with moderate-to-severe chronic hand eczema. Two new studies reinforce the efficacy and safety of Dupixent for the treatment of atopic dermatitis in children and adults. Stelara is now approved for pediatric patients, 6-11 years of age, with moderate to severe plaque psoriasis. Look for Rihanna’s new Fenty Skin line under the umbrella of skincare offerings. 

Advertisement

In This Series

View More

Advertisement